We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A proliferation-inducing ligand (APRIL) serum levels predict time to first treatment in patients affected by B-cell chronic lymphocytic leukemia.
- Authors
Tecchio, Cristina; Nichele, Ilaria; Mosna, Federico; Zampieri, Francesca; Leso, Antonella; Al-Khaffaf, Ahmad; Veneri, Dino; Andreini, Angelo; Pizzolo, Giovanni; Ambrosetti, Achille
- Abstract
A proliferation-inducing ligand (APRIL), a tumor necrosis factor superfamily member involved in B-lymphocytes differentiation and survival, plays a role in protecting B-Cell Chronic lymphocytic leukemia (B-CLL) cells from apoptosis. Having observed that APRIL serum (sAPRIL) levels were higher in B-CLL patients with CLL at diagnosis as compared to healthy donors (14.61±32.65 vs. 4.19±3.42 ng/mL; P<0.001), we tested the correlation existing in these patients between sAPRIL, clinical-biological parameters and disease progression.
- Publication
European journal of haematology, 2011, Vol 87, Issue 3, p228
- ISSN
1600-0609
- Publication type
Journal Article
- DOI
10.1111/j.1600-0609.2011.01650.x